Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Follow-on nets $95.9mm for bluebird bio

Executive Summary

Just one week after acquiring Precision Genome Engineering Inc., bluebird bio Inc. (gene therapies for genetic and orphan diseases) netted $95.9mm through the follow-on public sale of 3mm common shares at $34 each. Proceeds will help fund a Phase II/III trial for Lenti-D in childhood cerebral adrenoleukodystrophy and a Phase I/II study of LentiGlobin for beta-thalassemia major and sickle cell disease.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies